Table 3:
Summaries of pooled effects of treatment in different outcomes
| Outcome | Subgroup | Studies | Statistical method | Pooled effect estimate | Test of overall effect | Heterogeneity I2(%) |
|---|---|---|---|---|---|---|
| All-cause mortality at 12 years | All patients | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.89 (0.78 to 1.02) | Z= 1.67 P(Z)= 0.1 |
0 |
| Age< 65 years | 2 | Risk Ratio (IV, Random, 95% CI) | 0.78 (0.60 to 1.01) | Z= 0.99 P(Z)= 0.32 |
90 | |
| Age ≥65 years | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.93 (0.80 to 1.09) | Z=0.92 P(Z)= 0.36 |
0 | |
| prostate-cause mortality at 12 years | All patients | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.60 (0.38 to 0.94) | Z= 2.22 P(Z)=0.03 |
0 |
| Age<65 years | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.46 (0.27 to 0.76) | Z= 2.99 P(Z)= 0.003 |
0 | |
| Age ≥65 years | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.87 (0.56 to 1.34) | Z=0.63 P(Z)= 0.53 |
0 | |
| PSA>10 | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.61 (0.38 to 0.98) | Z=2.05 P(Z)= 0.04 |
0 | |
| PSA≤10 | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.77 (0.44 to 1.36) | Z=0.92 P(Z)= 0.36 |
0 | |
| Gleason<7 | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.61 (0.35 to 1.06) | Z=1.76 P(Z)= 0.08 |
0 | |
| Gleason≥7 | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.56 (0.34 to 0.92) | Z=2.29 P(Z)= 0.02 |
0 | |
| Distant metastases at 12 years | All patients | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.55 (0.36 to 0.85) | Z= 2.72 P(Z)= 0.007 |
44 |
| Age<65 years | 2 | Risk Ratio (IV, Fixed, 95% CI) | 0.53 (0.36 to 0.78) | Z= 3.18 P(Z)= 0.001 |
0 | |
| Age ≥65 years | 2 | Risk Ratio (IV, Random, 95% CI) | 0.55 (0.23 to 1.30) | Z= 1.36 P(Z)= 0.17 |
72 | |
| Erectile dysfunction at 2 years | All patients | 2 | Risk Ratio (M-H, Fixed, 95% CI) | 1.88 (1.65 to 2.15) | Z= 9.26 P(Z)<0.00001 |
0 |
| Urinary incontinence at 2 years | All patients | 2 | Risk Ratio (M-H, Fixed, 95% CI) | 2.95 (1.91 to 4.56) | Z= 4.88 P(Z)<0.00001 |
0 |